{
  "protocol": {
    "name": "Ketamine Infusion Therapy for Treatment-Resistant Depression",
    "version": "1.0",
    "therapy_type": "ketamine_psychedelic",
    "condition_treated": "Treatment-Resistant Depression (TRD), Major Depressive Disorder",
    "evidence_level": "clinical_practice",
    "overview": "Evidence-based ketamine infusion protocol for treatment-resistant depression. Uses sub-anesthetic doses of intravenous ketamine (0.5 mg/kg) administered over 40 minutes in a monitored clinical setting. Based on extensive research demonstrating rapid antidepressant effects, often within hours to days.",
    "duration_weeks": 4,
    "total_sessions": 11,
    "evidence_sources": [
      "Zarate CA, et al. Arch Gen Psychiatry. 2006;63(8):856-864 (PMID: 16894061)",
      "Murrough JW, et al. Am J Psychiatry. 2013;170(10):1134-1142 (PMID: 23982301)",
      "Wilkinson ST, et al. Am J Psychiatry. 2018;175(1):43-50 (PMID: 28969441)",
      "Feder A, et al. JAMA Psychiatry. 2021;78(5):478-486 (PMID: 33533876)",
      "American Psychiatric Association Guidelines on Ketamine for Depression",
      "Consensus Statement on Ketamine in Mood Disorders (2017)"
    ]
  },
  "steps": [
    {
      "sequence_order": 1,
      "step_type": "screening",
      "title": "Comprehensive Psychiatric Evaluation",
      "description": "Detailed psychiatric assessment to confirm treatment-resistant depression, assess severity, evaluate prior treatment history, and determine appropriateness for ketamine therapy.",
      "duration_minutes": 90,
      "required_roles": ["psychiatrist", "psychiatric_nurse_practitioner"],
      "clinical_scales": [
        "MADRS (Montgomery-Åsberg Depression Rating Scale)",
        "PHQ-9 (Patient Health Questionnaire-9)",
        "GAD-7 (Generalized Anxiety Disorder-7)",
        "QIDS-SR-16 (Quick Inventory of Depressive Symptomatology)",
        "Columbia-Suicide Severity Rating Scale (C-SSRS)",
        "Patient Health Questionnaire-15 (PHQ-15) for somatic symptoms"
      ],
      "diagnostic_criteria": {
        "depression_severity": "MADRS ≥ 20 (moderate to severe) OR PHQ-9 ≥ 10",
        "trd_criteria": "Failed at least 2 adequate antidepressant trials in current episode",
        "adequate_trial_definition": "≥6 weeks at therapeutic dose",
        "current_episode_duration": "≥ 4 weeks"
      },
      "documentation_requirements": {
        "psychiatric_history": [
          "Detailed depression history (onset, course, prior episodes)",
          "Complete medication history with specific agents, doses, durations, responses",
          "Prior psychiatric hospitalizations",
          "Suicide attempt history and current suicidal ideation",
          "Comorbid psychiatric diagnoses (anxiety, PTSD, OCD, etc.)",
          "Substance use history (critical for ketamine - abuse potential)",
          "Prior response to ketamine or other psychedelics"
        ],
        "treatment_resistance_documentation": [
          "List of all antidepressant trials with adequacy assessment",
          "Response to psychotherapy",
          "Response to other treatments (ECT, TMS, etc.)",
          "Barriers to treatment response"
        ],
        "current_treatment": [
          "Current medications (psychiatric and medical)",
          "Current psychotherapy",
          "Recent medication changes"
        ]
      }
    },
    {
      "sequence_order": 2,
      "step_type": "screening",
      "title": "Medical Clearance & Cardiovascular Assessment",
      "description": "Comprehensive medical evaluation with emphasis on cardiovascular health, as ketamine increases blood pressure and heart rate. Essential safety screening before ketamine administration.",
      "duration_minutes": 60,
      "required_roles": ["physician", "nurse_practitioner", "cardiologist_if_indicated"],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "temperature", "weight", "height", "bmi"],
        "critical_parameters": {
          "baseline_bp": "Must be <140/90 mmHg (uncontrolled hypertension is contraindication)",
          "baseline_hr": "Must be 50-100 bpm (evaluate if outside range)"
        }
      },
      "lab_tests_required": [
        "Complete Blood Count (CBC)",
        "Comprehensive Metabolic Panel (CMP) - especially liver and kidney function",
        "Thyroid Function Tests (TSH, Free T4)",
        "Electrocardiogram (ECG) - mandatory for all patients",
        "Urine drug screen (assess for substance use)",
        "Pregnancy test (for women of childbearing potential)"
      ],
      "cardiovascular_assessment": {
        "ecg_review": [
          "Rule out arrhythmias",
          "Assess QTc interval",
          "Look for ischemic changes",
          "Evaluate conduction abnormalities"
        ],
        "risk_stratification": [
          "History of cardiovascular disease",
          "Uncontrolled hypertension (BP >140/90)",
          "Recent myocardial infarction (<6 months)",
          "Unstable angina",
          "Congestive heart failure",
          "Cerebrovascular disease or stroke history",
          "Intracranial mass or increased intracranial pressure"
        ]
      },
      "other_medical_screening": [
        "Hepatic function (ketamine metabolized by liver)",
        "Renal function",
        "Thyroid disorders (treat if present)",
        "Active substance use disorders",
        "Urological issues (ketamine can cause cystitis with chronic use)"
      ]
    },
    {
      "sequence_order": 3,
      "step_type": "screening",
      "title": "Substance Use & Abuse Potential Assessment",
      "description": "Thorough evaluation of substance use history and abuse potential, given ketamine's dissociative properties and potential for misuse. Critical for patient selection and risk mitigation.",
      "duration_minutes": 30,
      "required_roles": ["psychiatrist", "addiction_specialist_if_indicated"],
      "assessment_components": {
        "current_substance_use": [
          "Alcohol use (quantity, frequency, pattern)",
          "Cannabis use",
          "Stimulant use (cocaine, amphetamines)",
          "Opioid use",
          "Benzodiazepine use",
          "Hallucinogen use (LSD, psilocybin, MDMA)",
          "Dissociative use (ketamine, DXM, PCP)",
          "Other recreational drugs"
        ],
        "substance_use_history": [
          "Past substance use disorders",
          "Treatment for addiction",
          "Recovery status and duration of sobriety",
          "Relapse history"
        ],
        "risk_assessment": [
          "Addictive personality traits",
          "Impulsivity assessment",
          "Family history of addiction",
          "Motivation for ketamine treatment (seeking therapeutic effect vs. dissociative high)",
          "Support system and accountability"
        ]
      },
      "risk_mitigation_strategies": [
        "Informed consent about abuse potential",
        "Treatment agreement outlining expectations",
        "Structured protocol with limited take-home options",
        "Monitoring for signs of misuse",
        "Involving family/support persons with consent"
      ]
    },
    {
      "sequence_order": 4,
      "step_type": "decision_point",
      "title": "Eligibility Determination & Route Selection",
      "description": "Evaluate all screening data to determine patient eligibility for ketamine therapy and select optimal administration route (IV vs. intranasal vs. oral).",
      "duration_minutes": 30,
      "required_roles": ["psychiatrist", "medical_director"],
      "evaluation_rules": {
        "type": "safety_assessment",
        "absolute_contraindications": [
          {
            "condition": "uncontrolled_hypertension",
            "criteria": "BP persistently >140/90 despite medication",
            "action": "exclude_until_controlled",
            "rationale": "Ketamine increases BP acutely; risk of hypertensive crisis"
          },
          {
            "condition": "recent_cardiovascular_event",
            "criteria": "MI, stroke, or unstable angina within 6 months",
            "action": "exclude_from_treatment",
            "rationale": "Cardiovascular stress from ketamine too risky"
          },
          {
            "condition": "severe_heart_failure",
            "criteria": "NYHA Class III-IV heart failure",
            "action": "exclude_from_treatment",
            "rationale": "Cannot tolerate hemodynamic changes"
          },
          {
            "condition": "intracranial_pathology",
            "criteria": "Brain tumor, aneurysm, increased ICP",
            "action": "exclude_from_treatment",
            "rationale": "Ketamine increases intracranial pressure"
          },
          {
            "condition": "active_psychosis",
            "criteria": "Current psychotic symptoms",
            "action": "exclude_from_treatment",
            "rationale": "Ketamine may worsen psychotic symptoms"
          },
          {
            "condition": "schizophrenia_spectrum",
            "criteria": "Diagnosis of schizophrenia or schizoaffective disorder",
            "action": "exclude_from_treatment",
            "rationale": "Risk of exacerbating psychosis"
          },
          {
            "condition": "hyperthyroidism_uncontrolled",
            "criteria": "Untreated or poorly controlled hyperthyroidism",
            "action": "defer_until_controlled",
            "rationale": "Ketamine may precipitate thyroid storm"
          },
          {
            "condition": "pregnancy_breastfeeding",
            "criteria": "Currently pregnant or breastfeeding",
            "action": "exclude_from_treatment",
            "rationale": "Safety not established"
          },
          {
            "condition": "severe_liver_disease",
            "criteria": "Cirrhosis, hepatic failure",
            "action": "exclude_from_treatment",
            "rationale": "Impaired ketamine metabolism"
          },
          {
            "condition": "active_substance_use_disorder",
            "criteria": "Current moderate-severe SUD (except tobacco)",
            "action": "defer_until_treatment",
            "rationale": "High risk of ketamine misuse"
          }
        ],
        "relative_contraindications": [
          {
            "condition": "controlled_hypertension",
            "management": "Close BP monitoring, ensure medications optimized, may proceed with caution"
          },
          {
            "condition": "bipolar_disorder",
            "management": "Ensure mood stabilizer on board, monitor for mania, may proceed with caution"
          },
          {
            "condition": "substance_use_history",
            "management": "Enhanced monitoring, treatment agreement, support person involvement"
          },
          {
            "condition": "dissociative_disorder",
            "management": "Careful consideration, may worsen dissociation, proceed only if benefits outweigh risks"
          }
        ],
        "route_selection": {
          "intravenous_infusion": {
            "indications": "Gold standard, most evidence, best for acute treatment, controlled dosing",
            "advantages": ["Precise dosing", "Controlled onset and offset", "Most research support"],
            "disadvantages": ["IV access required", "Clinical setting needed", "More expensive"],
            "typical_protocol": "0.5 mg/kg over 40 minutes, 2-3 times per week for 2-4 weeks"
          },
          "intranasal_esketamine": {
            "indications": "FDA-approved for TRD (Spravato), convenient, no IV needed",
            "advantages": ["FDA-approved", "Self-administered (supervised)", "No IV needed"],
            "disadvantages": ["More expensive", "Insurance issues", "Nasal irritation", "Variable absorption"],
            "typical_protocol": "56-84 mg intranasally twice weekly, requires 2-hour observation",
            "notes": "Spravato has REMS program requirements"
          },
          "oral_ketamine": {
            "indications": "Maintenance therapy, cost-effective, at-home use possible",
            "advantages": ["Convenient", "Less expensive", "Possible at-home use with proper monitoring"],
            "disadvantages": ["Lower bioavailability", "Variable absorption", "Less evidence", "Abuse potential with at-home use"],
            "typical_protocol": "0.5-1.0 mg/kg oral, 2-3 times per week"
          },
          "intramuscular_ketamine": {
            "indications": "Alternative when IV access difficult",
            "advantages": ["No IV needed", "Predictable absorption"],
            "disadvantages": ["Painful", "Less common in practice"],
            "typical_protocol": "0.5 mg/kg IM"
          }
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "iv_ketamine_selected",
          "next_step": 5,
          "description": "IV infusion protocol - gold standard for acute treatment"
        },
        {
          "outcome_id": "intranasal_esketamine_selected",
          "next_step": 5,
          "description": "Intranasal esketamine (Spravato) protocol"
        },
        {
          "outcome_id": "excluded_from_treatment",
          "next_step": "exit_protocol",
          "description": "Contraindication present, refer to alternative treatments"
        }
      ]
    },
    {
      "sequence_order": 5,
      "step_type": "preparation",
      "title": "Pre-Treatment Education & Informed Consent",
      "description": "Comprehensive patient education about ketamine therapy, expected effects, risks, benefits, treatment expectations, and obtaining detailed informed consent.",
      "duration_minutes": 60,
      "required_roles": ["psychiatrist", "nurse"],
      "education_topics": [
        "Mechanism of action (NMDA receptor antagonist, rapid antidepressant)",
        "Expected timeline of response (often within hours to days)",
        "Dissociative effects during infusion (floating, detachment, perceptual changes)",
        "Duration of effects (dissociation lasts ~2 hours, antidepressant effects days to weeks)",
        "Treatment protocol (6 infusions over 2-4 weeks typically)",
        "Need for maintenance (often required to sustain benefits)",
        "Safety monitoring during infusions",
        "Common side effects (dissociation, nausea, elevated BP)",
        "Rare but serious risks (hypertensive crisis, emergence reactions, bladder toxicity with chronic use)",
        "Abuse potential and safeguards",
        "Post-infusion restrictions (no driving for 24 hours, responsible adult required)",
        "Integration and psychotherapy to maximize benefits",
        "Costs and insurance coverage"
      ],
      "informed_consent_elements": [
        "Off-label use (except Spravato which is FDA-approved)",
        "Expected benefits and limitations",
        "Alternative treatments available",
        "Risks and side effects",
        "Monitoring procedures",
        "Treatment agreement (no drug diversion, adherence to protocol)",
        "Right to discontinue treatment",
        "Research participation (if applicable)"
      ],
      "practical_preparation": [
        "NPO guidelines: no food 4 hours before, clear liquids okay up to 2 hours before",
        "Continue most medications (verify with physician)",
        "Arrange ride home after each infusion",
        "Wear comfortable clothing",
        "Bring music or playlist if desired (some patients prefer)",
        "Clear schedule day of infusion (no work, no responsibilities)"
      ]
    },
    {
      "sequence_order": 6,
      "step_type": "intervention",
      "title": "Ketamine Infusion Session 1",
      "description": "First ketamine infusion session. Standard dose of 0.5 mg/kg IV over 40 minutes with continuous monitoring. Critical to establish tolerance, assess response, and refine protocol.",
      "duration_minutes": 120,
      "required_roles": ["physician", "nurse", "mental_health_clinician"],
      "pre_infusion_procedures": {
        "arrival_and_setup": [
          "Patient check-in and vital signs",
          "Brief psychiatric assessment (mood, suicidal ideation)",
          "Administer baseline scales (if first infusion or weekly check)",
          "IV line placement (typically 20-22 gauge)",
          "Patient positioned in comfortable recliner",
          "Monitoring equipment attached (BP cuff, pulse oximetry, telemetry if indicated)"
        ],
        "baseline_vitals": {
          "required": ["blood_pressure", "heart_rate", "respiratory_rate", "oxygen_saturation", "temperature"],
          "pre_infusion_check": "Ensure BP <140/90, HR 50-100 before starting"
        },
        "pre_medications": [
          "Anti-nausea medication optional (ondansetron 4 mg IV if patient prone to nausea)",
          "Anxiolytic rarely needed (benzodiazepine may reduce ketamine efficacy)"
        ]
      },
      "infusion_protocol": {
        "dose_calculation": "0.5 mg/kg based on actual body weight",
        "example": "For 70 kg patient: 35 mg ketamine",
        "preparation": "Ketamine diluted in 50-100 mL normal saline",
        "infusion_rate": "Administered over 40 minutes via infusion pump",
        "monitoring_location": "Comfortable private room, low lighting, minimal stimulation"
      },
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "respiratory_rate", "oxygen_saturation"],
        "frequency": "Every 10 minutes during infusion and 30 minutes post-infusion",
        "alert_parameters": {
          "systolic_bp": "> 180 mmHg or increase >40 mmHg from baseline",
          "diastolic_bp": "> 110 mmHg",
          "heart_rate": "> 110 bpm or increase >30 bpm from baseline",
          "oxygen_saturation": "< 92%",
          "respiratory_rate": "< 10 or > 24 breaths/min"
        },
        "management_if_elevated": {
          "hypertension": [
            "First line: reassurance, deep breathing, reducing stimulation",
            "If persistent BP >180/110: slow or pause infusion",
            "If severe or symptomatic: antihypertensive (labetalol 10-20 mg IV or hydralazine 10 mg IV)",
            "Resume infusion at slower rate once BP controlled"
          ],
          "tachycardia": "Usually resolves spontaneously; beta-blocker rarely needed",
          "respiratory_depression": "Very rare at 0.5 mg/kg; stimulate patient, reduce infusion rate, have airway support available"
        }
      },
      "dissociation_monitoring": {
        "scales": "CADSS (Clinician-Administered Dissociative States Scale) - administered at 40 min and 80 min",
        "observation": [
          "Level of dissociation (mild, moderate, profound)",
          "Patient's ability to communicate",
          "Emotional state (calm, anxious, distressed)",
          "Perceptual distortions reported"
        ],
        "patient_experience": [
          "Typical onset: 5-10 minutes into infusion",
          "Peak: 30-40 minutes (end of infusion)",
          "Effects: floating sensation, detachment from body/surroundings, visual distortions, time distortion, dreamlike state",
          "Resolution: gradual over 1-2 hours post-infusion"
        ]
      },
      "supportive_care_during_infusion": {
        "environment": [
          "Dim lighting, quiet room",
          "Minimal conversation or stimulation",
          "Eyeshades available if patient prefers",
          "Soft music (patient choice or ambient)",
          "Blanket for warmth"
        ],
        "clinician_presence": [
          "Nurse remains in room continuously",
          "Physician nearby and available",
          "Mental health clinician checks in periodically",
          "Calm, reassuring presence"
        ],
        "managing_distress": [
          "Verbal reassurance: 'You're safe, this is temporary, you're doing great'",
          "Grounding techniques if needed: touch, orientation to reality",
          "Rarely: slow infusion if severe distress",
          "Very rarely: benzodiazepine rescue (impairs antidepressant effect, avoid if possible)"
        ]
      },
      "post_infusion_monitoring": {
        "duration": "Minimum 60-90 minutes post-infusion",
        "vitals": "Every 15-30 minutes until stable and near baseline",
        "dissociation_resolution": "Patient should be alert, oriented, communicative before discharge",
        "mood_assessment": "Brief check-in about mood changes",
        "side_effects": "Assess nausea, headache, dizziness",
        "discharge_criteria": [
          "Vital signs stable and near baseline",
          "Dissociative effects resolved (can walk, talk normally)",
          "No acute distress",
          "Responsible adult present to drive patient home",
          "Patient understands post-infusion instructions"
        ]
      },
      "post_infusion_instructions": [
        "Rest at home for remainder of day",
        "No driving or operating machinery for 24 hours",
        "Light meals (may have some nausea)",
        "Stay hydrated",
        "No alcohol or recreational drugs",
        "Safe to take usual medications",
        "Call clinic if severe headache, persistent nausea, chest pain, concerning symptoms",
        "Journal about experience if desired",
        "Next infusion scheduled in 2-4 days"
      ],
      "clinical_documentation": [
        "Dose administered and infusion completion",
        "Vital signs throughout session",
        "CADSS scores",
        "Behavioral observations",
        "Tolerability",
        "Any adverse events",
        "Subjective report of dissociative experience",
        "Early mood changes noted"
      ]
    },
    {
      "sequence_order": 7,
      "step_type": "intervention",
      "title": "Ketamine Infusion Sessions 2-3 (Week 1)",
      "description": "Second and third infusion sessions, typically scheduled 2-4 days apart during first week. Same protocol as Session 1 with ongoing assessment of tolerability and early response.",
      "duration_minutes": 120,
      "required_roles": ["physician", "nurse", "mental_health_clinician"],
      "session_structure": {
        "pre_infusion_check_in": [
          "How did you feel after last infusion?",
          "Any mood changes noticed?",
          "Sleep changes?",
          "Suicidal ideation assessment",
          "Side effects or concerns from previous infusion?",
          "Any interim substance use?"
        ],
        "infusion_protocol": "Same as Session 1: 0.5 mg/kg over 40 minutes",
        "vitals_monitoring": "Every 10 minutes during infusion, every 15-30 minutes for 90 min post-infusion",
        "dissociation_monitoring": "CADSS at 40 min and 80 min"
      },
      "response_monitoring": {
        "early_responders": "Some patients notice mood improvement within 24-72 hours of first or second infusion",
        "typical_timeline": "Most patients begin noticing effects after 2-4 infusions",
        "suicidal_ideation": "Often rapid reduction in suicidal thoughts (within hours to days)",
        "energy_and_motivation": "May increase before mood fully lifts"
      },
      "dose_adjustments": {
        "if_minimal_dissociation_session_1": "May consider increasing to 0.6-0.75 mg/kg for subsequent sessions",
        "if_excessive_distress_session_1": "May decrease to 0.4 mg/kg or slow infusion rate",
        "if_bp_very_elevated": "May need antihypertensive pre-treatment or dose reduction",
        "standard_approach": "Most patients continue 0.5 mg/kg for all sessions"
      }
    },
    {
      "sequence_order": 8,
      "step_type": "intervention",
      "title": "Ketamine Infusion Sessions 4-6 (Weeks 2-3)",
      "description": "Completion of acute treatment phase with infusions 4, 5, and 6. Scheduled 2-3 times per week. Assessment of cumulative response and planning for maintenance.",
      "duration_minutes": 120,
      "required_roles": ["physician", "nurse", "mental_health_clinician"],
      "session_structure": {
        "weekly_assessments": [
          "Administer PHQ-9, GAD-7 weekly (typically before Session 4)",
          "MADRS if being tracked",
          "Suicidal ideation (C-SSRS)",
          "Side effects review",
          "Functional improvement assessment"
        ],
        "infusion_protocol": "Continue same dose (typically 0.5 mg/kg over 40 minutes)",
        "cumulative_effects": "Antidepressant response typically builds with each infusion",
        "patient_education": "Discuss maintenance planning, duration of effects, relapse prevention"
      },
      "response_patterns": {
        "robust_responders": "50-70% experience significant improvement (≥50% symptom reduction)",
        "partial_responders": "Additional 20-30% have moderate improvement",
        "non_responders": "10-20% have minimal to no benefit",
        "suicidal_ideation": "Often dramatic reduction even in partial responders",
        "anxiety": "Often improves along with depression"
      }
    },
    {
      "sequence_order": 9,
      "step_type": "followup",
      "title": "End of Acute Phase Assessment (Week 3-4)",
      "description": "Comprehensive assessment after completing 6 infusions to evaluate treatment response and determine next steps (maintenance, additional acute infusions, or alternative treatments).",
      "duration_minutes": 60,
      "required_roles": ["psychiatrist", "mental_health_clinician"],
      "clinical_scales": [
        "MADRS",
        "PHQ-9",
        "GAD-7",
        "QIDS-SR-16",
        "C-SSRS",
        "Clinical Global Impression - Improvement (CGI-I)",
        "Patient Global Impression - Change (PGI-C)",
        "Sheehan Disability Scale (functional improvement)"
      ],
      "assessment_components": {
        "symptom_response": [
          "Depression severity compared to baseline",
          "Percentage improvement in MADRS or PHQ-9",
          "Response status: ≥50% improvement",
          "Remission status: MADRS <10 or PHQ-9 <5",
          "Suicidal ideation changes",
          "Anxiety symptom changes",
          "Functional improvement (work, relationships, self-care)"
        ],
        "tolerability_review": [
          "Overall tolerability of infusions",
          "Side effects experienced",
          "Dissociative experiences (positive, neutral, or negative)",
          "Cardiovascular tolerability",
          "Impact on daily life"
        ],
        "patient_perspective": [
          "Subjective sense of benefit",
          "Quality of life changes",
          "What's better, what's still difficult",
          "Satisfaction with treatment",
          "Interest in continuing"
        ]
      }
    },
    {
      "sequence_order": 10,
      "step_type": "decision_point",
      "title": "Treatment Response Evaluation & Maintenance Planning",
      "description": "Clinical decision-making based on response to acute ketamine treatment. Determine need for maintenance infusions, frequency, and duration of continued treatment.",
      "duration_minutes": 30,
      "required_roles": ["psychiatrist"],
      "evaluation_rules": {
        "type": "response_assessment",
        "response_categories": [
          {
            "category": "remission",
            "definition": "MADRS <10 or PHQ-9 <5, functional recovery",
            "prevalence": "30-40% of patients",
            "recommendation": "Maintenance protocol to sustain remission",
            "maintenance_frequency": "Start with infusions every 2-4 weeks, titrate to individual need"
          },
          {
            "category": "response",
            "definition": "≥50% symptom reduction but still symptomatic",
            "prevalence": "30-40% of patients",
            "recommendation": "Maintenance protocol, consider adjunctive treatments",
            "maintenance_frequency": "Every 1-3 weeks initially"
          },
          {
            "category": "partial_response",
            "definition": "25-49% improvement",
            "prevalence": "10-20% of patients",
            "recommendation": "Consider additional acute infusions, increase dose, or add adjunctive therapy",
            "options": [
              "2-4 additional infusions at current dose",
              "Increase dose to 0.75 mg/kg",
              "Add psychotherapy",
              "Optimize concurrent medications",
              "Consider alternative routes (intranasal)"
            ]
          },
          {
            "category": "non_response",
            "definition": "<25% improvement",
            "prevalence": "10-20% of patients",
            "recommendation": "Discontinue ketamine, pursue alternative treatments",
            "alternatives": [
              "ECT (electroconvulsive therapy)",
              "TMS (transcranial magnetic stimulation)",
              "Psilocybin-assisted therapy (if available)",
              "Medication optimization",
              "Intensive psychotherapy"
            ]
          }
        ],
        "maintenance_protocols": {
          "standard_approach": {
            "initial_frequency": "Every 2-4 weeks",
            "titration_strategy": "Increase interval gradually if sustained response; decrease if symptoms return",
            "typical_patterns": [
              "Some patients stable on monthly infusions",
              "Others need every 2 weeks",
              "Some need weekly long-term"
            ],
            "duration": "Often 6-12 months, some patients require indefinite maintenance",
            "goal": "Find minimum frequency that maintains response"
          },
          "relapse_prevention": [
            "Continue concurrent antidepressants (may provide additive benefit)",
            "Ongoing psychotherapy strongly recommended",
            "Early intervention if symptoms begin to return (bring infusion forward)",
            "Lifestyle factors (sleep, exercise, stress management, social connection)"
          ]
        },
        "factors_affecting_maintenance_need": [
          "Severity of baseline depression (more severe → longer maintenance)",
          "Duration of current episode (longer episode → longer maintenance)",
          "Number of prior episodes (recurrent depression → longer maintenance)",
          "Concurrent treatments (psychotherapy, medications)",
          "Life stressors and supports",
          "Individual pharmacodynamics (some patients metabolize faster)"
        ],
        "discontinuation_considerations": {
          "appropriate_timing": "After sustained remission for 6-12 months with good life circumstances",
          "approach": "Gradually lengthen intervals between infusions",
          "monitoring": "Close follow-up for early signs of relapse",
          "relapse_management": "Resume infusions at previous effective frequency"
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "start_maintenance",
          "next_step": 11,
          "description": "Patient responded, begin maintenance infusion protocol"
        },
        {
          "outcome_id": "additional_acute_infusions",
          "next_step": 8,
          "description": "Partial response, continue with additional infusions"
        },
        {
          "outcome_id": "discontinue_ketamine",
          "next_step": "exit_protocol",
          "description": "Insufficient response, pursue alternative treatments"
        }
      ]
    },
    {
      "sequence_order": 11,
      "step_type": "followup",
      "title": "Maintenance Ketamine Infusions",
      "description": "Ongoing ketamine infusions at individualized intervals to maintain antidepressant response. Typically every 2-4 weeks initially, adjusted based on symptom trajectory.",
      "duration_minutes": 120,
      "required_roles": ["physician", "nurse"],
      "maintenance_structure": {
        "infusion_protocol": "Same as acute phase: 0.5 mg/kg over 40 minutes (unless dose was adjusted)",
        "initial_frequency": "Every 2-4 weeks",
        "monitoring": {
          "vitals": "Every 10 minutes during infusion as in acute phase",
          "scales": "PHQ-9 and GAD-7 before each infusion; MADRS monthly",
          "suicidal_ideation": "C-SSRS at each visit",
          "functional_status": "Sheehan Disability Scale monthly or quarterly"
        },
        "interval_adjustment": {
          "if_symptoms_returning_before_scheduled_infusion": "Decrease interval (e.g., from 4 weeks to 3 weeks)",
          "if_sustained_remission_well_past_scheduled_infusion": "Cautiously increase interval (e.g., from 3 weeks to 4 weeks)",
          "goal": "Find longest interval that maintains remission"
        }
      },
      "long_term_monitoring": {
        "bladder_health": {
          "concern": "Chronic ketamine use can cause bladder toxicity (ketamine cystitis)",
          "risk": "Much lower with therapeutic dosing vs. recreational abuse, but monitor",
          "screening": [
            "Ask about urinary symptoms (frequency, urgency, pain, hematuria) at each visit",
            "If symptoms develop: urology referral, urinalysis, consider cystoscopy",
            "May need to discontinue ketamine if cystitis develops"
          ]
        },
        "cognitive_function": {
          "concern": "Chronic ketamine might affect memory or cognition",
          "monitoring": "Subjective assessment; formal neuropsych testing if concerns arise",
          "evidence": "Limited data on long-term therapeutic ketamine; most studies reassuring"
        },
        "abuse_potential": {
          "monitoring": [
            "Signs of misuse (requesting early refills, seeking ketamine from other sources)",
            "Increasing tolerance (needing higher doses)",
            "Preoccupation with dissociative effects rather than antidepressant effects",
            "Urine drug screens periodically if concerns"
          ],
          "red_flags": "If abuse suspected, discontinue and refer to addiction treatment"
        },
        "cardiovascular": {
          "monitoring": "Baseline ECG annually; more frequent if concerns",
          "blood_pressure": "Check at each infusion; ensure home BP remains controlled"
        },
        "hepatic_function": {
          "monitoring": "LFTs every 6-12 months (ketamine metabolized by liver)"
        }
      },
      "adjunctive_treatments": {
        "psychotherapy": [
          "Strongly recommended to maintain gains",
          "CBT, DBT, or other evidence-based therapy",
          "Integration work (processing insights from dissociative experiences)",
          "Relapse prevention strategies"
        ],
        "medications": [
          "Continue or optimize concurrent antidepressants",
          "Ketamine may allow reduction of other medications in some cases",
          "Avoid benzodiazepines if possible (may impair ketamine efficacy)"
        ],
        "lifestyle": [
          "Sleep hygiene",
          "Regular exercise",
          "Stress management",
          "Social connection",
          "Meaningful activities"
        ]
      }
    }
  ],
  "ongoing_monitoring": {
    "during_maintenance_phase": {
      "frequency": "At each infusion visit",
      "assessments": [
        "PHQ-9, GAD-7 at each visit",
        "MADRS monthly",
        "C-SSRS at each visit",
        "Sheehan Disability Scale quarterly",
        "Bladder symptom screening at each visit",
        "Cognitive function subjective assessment",
        "LFTs every 6-12 months",
        "ECG annually"
      ]
    },
    "long_term_outcomes": {
      "durability": "Many patients maintain response for months to years with maintenance infusions",
      "relapse_rates": "Higher if maintenance discontinued prematurely",
      "quality_of_life": "Often significant improvement in functioning and life satisfaction",
      "safety": "Generally well-tolerated long-term at therapeutic doses"
    }
  },
  "safety_monitoring": {
    "absolute_contraindications": [
      "Uncontrolled hypertension",
      "Recent MI, stroke, or unstable angina (<6 months)",
      "Severe heart failure (NYHA Class III-IV)",
      "Intracranial mass, aneurysm, increased ICP",
      "Schizophrenia or active psychosis",
      "Severe hepatic impairment",
      "Pregnancy or breastfeeding",
      "Active moderate-severe substance use disorder",
      "Hyperthyroidism (uncontrolled)"
    ],
    "adverse_effects_monitoring": [
      {
        "effect": "Dissociation during infusion",
        "frequency": "Universal (desired effect at therapeutic doses)",
        "management": "Supportive care, reassurance; resolves post-infusion",
        "duration": "1-2 hours"
      },
      {
        "effect": "Elevated blood pressure",
        "frequency": "Very common (70-80%)",
        "management": "Usually mild; slow infusion or antihypertensive if severe",
        "duration": "During and shortly after infusion"
      },
      {
        "effect": "Nausea/vomiting",
        "frequency": "Common (20-30%)",
        "management": "Prophylactic ondansetron",
        "duration": "During infusion, occasionally after"
      },
      {
        "effect": "Headache",
        "frequency": "Occasional (10-15%)",
        "management": "Acetaminophen or NSAIDs post-infusion",
        "duration": "Hours to 1 day"
      },
      {
        "effect": "Dizziness/vertigo",
        "frequency": "Common (30-40%)",
        "management": "Resolve spontaneously; ambulate with assistance",
        "duration": "1-2 hours post-infusion"
      },
      {
        "effect": "Anxiety/panic during infusion",
        "frequency": "Occasional (5-10%)",
        "management": "Reassurance, grounding; rarely benzodiazepine",
        "duration": "During infusion"
      },
      {
        "effect": "Emergence reactions (agitation, confusion)",
        "frequency": "Rare (1-3%)",
        "management": "Benzodiazepine, supportive care, monitor until resolved",
        "duration": "Minutes to hours"
      },
      {
        "effect": "Bladder toxicity (cystitis)",
        "frequency": "Rare with therapeutic use (<1%), more common with chronic abuse",
        "management": "Urology referral, discontinue ketamine",
        "duration": "Can be chronic if severe"
      },
      {
        "effect": "Cognitive impairment",
        "frequency": "Unclear; likely rare with therapeutic dosing",
        "management": "Monitor subjectively; neuropsych testing if concerns; consider discontinuation",
        "duration": "Unclear"
      },
      {
        "effect": "Abuse/dependence",
        "frequency": "Low in monitored therapeutic setting (<5%), higher in vulnerable individuals",
        "management": "Screen carefully, monitor for signs, discontinue if misuse",
        "duration": "Ongoing if develops"
      }
    ],
    "emergency_protocols": {
      "hypertensive_crisis": "BP >200/120 or symptomatic: stop infusion, IV antihypertensive (labetalol, hydralazine), cardiology consult, transfer if unstable",
      "severe_emergence_reaction": "Benzodiazepine (lorazepam 1-2 mg IV/IM), supportive care, monitor until resolved, psychiatry consult",
      "cardiovascular_event": "Chest pain, arrhythmia: stop infusion, ECG, cardiac monitoring, emergency medicine/cardiology consult, transfer if needed",
      "respiratory_depression": "Very rare at 0.5 mg/kg but monitor: stimulate patient, supplemental O2, airway support, stop infusion",
      "severe_psychotic_reaction": "Benzodiazepine, antipsychotic if needed, psychiatry consult, possible hospitalization"
    }
  },
  "special_populations": {
    "elderly_patients": {
      "considerations": [
        "Higher cardiovascular risk - thorough cardiac clearance",
        "May be more sensitive to dissociative effects",
        "Consider lower starting dose (0.4 mg/kg)",
        "Enhanced monitoring during infusions",
        "Careful fall risk assessment post-infusion"
      ]
    },
    "bipolar_depression": {
      "considerations": [
        "Risk of inducing mania/hypomania",
        "Ensure mood stabilizer on board",
        "Close monitoring for mood elevation",
        "May still be beneficial for bipolar depression",
        "Consider lower dose or slower infusion"
      ]
    },
    "comorbid_ptsd": {
      "considerations": [
        "Ketamine shows promise for PTSD in addition to depression",
        "Dissociative effects may be triggering for some trauma survivors",
        "Trauma-informed approach essential",
        "Enhanced preparation and support",
        "Psychotherapy integration critical"
      ]
    },
    "patients_with_substance_use_history": {
      "considerations": [
        "Higher risk of ketamine misuse",
        "Require careful screening and ongoing monitoring",
        "Treatment agreement essential",
        "Consider involving support person",
        "Intranasal or oral formulations have higher abuse potential than supervised IV",
        "Close follow-up and accountability measures"
      ]
    }
  },
  "integration_and_psychotherapy": {
    "importance": "Ketamine should not be standalone treatment; psychotherapy integration enhances and sustains outcomes",
    "recommended_approaches": [
      "Ketamine-Assisted Psychotherapy (KAP): Psychotherapy sessions before, during, and after infusions",
      "Cognitive-Behavioral Therapy (CBT): Evidence-based for depression",
      "Mindfulness-Based Cognitive Therapy (MBCT): Relapse prevention",
      "Acceptance and Commitment Therapy (ACT): Values-based living",
      "Psychodynamic therapy: Processing insights from dissociative experiences"
    ],
    "integration_sessions": {
      "timing": "Within 1-2 days after each infusion ideally",
      "focus": [
        "Processing dissociative experience and any insights",
        "Connecting experience to therapeutic goals",
        "Translating insights into behavioral changes",
        "Addressing emotions or content that arose",
        "Building on momentum of improved mood"
      ]
    }
  },
  "cost_and_access_considerations": {
    "iv_ketamine": {
      "typical_cost": "$400-800 per infusion",
      "insurance": "Often not covered (off-label); improving with more evidence",
      "acute_phase_cost": "$2400-4800 for 6 infusions",
      "maintenance_cost": "$400-800 per month (if monthly infusions)"
    },
    "intranasal_esketamine": {
      "typical_cost": "$600-900 per dose (varies by dose)",
      "insurance": "Better coverage (FDA-approved) but often requires prior authorization",
      "REMS_requirements": "Must be administered in certified clinic with observation"
    },
    "access_barriers": [
      "High out-of-pocket cost",
      "Limited number of providers offering ketamine",
      "Geographic limitations (mostly urban centers)",
      "Time commitment (infusion visits)",
      "Transportation needs (cannot drive after)"
    ]
  },
  "clinical_pearls": [
    "Ketamine provides rapid relief often within hours to days - transformative for suicidal patients",
    "Most robust evidence for treatment-resistant depression, but also used for other indications",
    "Dissociation is part of the therapeutic effect - don't try to eliminate it",
    "Blood pressure elevation is expected and usually mild - monitor but don't overreact",
    "Maintenance is almost always needed - plan for long-term treatment",
    "Integration therapy maximizes and sustains benefits - ketamine alone is not enough",
    "Screen carefully for abuse potential - rare in monitored settings but real risk",
    "Not a cure - it's a tool to provide symptom relief and window for therapeutic work",
    "Works best as part of comprehensive treatment plan (therapy, lifestyle, support)"
  ]
}
